{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/",
 "dataUrl": "https://clearank.com/stock/bristol-myers-squibb-bmy/data.json",
 "title": "Bristol-Myers Squibb (BMY) Stock Forecast (2026)",
 "description": "Bristol-Myers Squibb Company (BMY) stock: Healthcare, Drug Manufacturers - General. $130.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Bristol-Myers Squibb Company (BMY)",
 "published": "2026-06-17T09:09:29+00:00",
 "modified": "2026-09-11T19:02:15.136+00:00",
 "generated": "2026-09-11T21:03:00.592Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "BMY",
  "name": "Bristol-Myers Squibb Company",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.bms.com"
 },
 "quote": {
  "price": 63.37,
  "previousClose": 63.75,
  "change": -0.38,
  "changePercent": -0.6,
  "open": 64.19,
  "high": 64.19,
  "low": 63.27,
  "volume": 321801,
  "averageVolume": 6694420,
  "marketCap": 130223059320,
  "fiftyTwoWeekHigh": 68.64,
  "fiftyTwoWeekLow": 42.52,
  "marketOpen": false,
  "asOf": "2026-09-11T19:02:14.000Z"
 },
 "statistics": {
  "pe": 14.04185,
  "eps": 4.54,
  "dividendYield": 0.03975704030922143,
  "beta": 0.227,
  "priceToSales": 2.6475635,
  "priceToBook": 5.8352404,
  "revenueTtm": 49186000896,
  "grossMargin": 0.7127880983581284,
  "returnOnEquity": 0.46598998
 },
 "technicals": {
  "rsi": 28.54,
  "macd": 0.26,
  "sma50": 63.42,
  "sma200": 58.49,
  "rsiSignal": "Oversold",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bullish",
  "rating": "Neutral"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 68,
  "analystTarget": 68,
  "analystCount": 28,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-11T19:02:14.000Z",
  "priceAtAnalysis": 63.37,
  "volatility": {
   "daily": 1.53,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 62.74,
  "aggressiveEntry": 63.37,
  "stopLoss": 60.67,
  "stopLossPercent": 3.3,
  "targets": [
   64.62,
   65.87,
   67.76
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 47.69,
    "base": 65.84,
    "upside90th": 90.9
   },
   {
    "year": 2028,
    "downside10th": 43.35,
    "base": 68.41,
    "upside90th": 107.95
   },
   {
    "year": 2029,
    "downside10th": 40.65,
    "base": 71.08,
    "upside90th": 124.27
   },
   {
    "year": 2030,
    "downside10th": 38.74,
    "base": 73.85,
    "upside90th": 140.77
   },
   {
    "year": 2031,
    "downside10th": 37.3,
    "base": 76.73,
    "upside90th": 157.83
   },
   {
    "year": 2032,
    "downside10th": 36.18,
    "base": 79.72,
    "upside90th": 175.67
   },
   {
    "year": 2033,
    "downside10th": 35.28,
    "base": 82.83,
    "upside90th": 194.45
   },
   {
    "year": 2034,
    "downside10th": 34.56,
    "base": 86.06,
    "upside90th": 214.29
   },
   {
    "year": 2035,
    "downside10th": 33.98,
    "base": 89.42,
    "upside90th": 235.32
   },
   {
    "year": 2036,
    "downside10th": 33.5,
    "base": 92.9,
    "upside90th": 257.63
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "BMY Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$64.19",
    "Day Range": "$63.27 to $64.19",
    "Prev Close": "$63.75",
    "Volume": "321.8K",
    "52-Week Range": "$42.52 to $68.64",
    "Market Cap": "$130.22B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-45%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "BMY Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, BMY beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "BMY Analysis",
   "text": [
    "At 28.54, Bristol-Myers Squibb Company's RSI is in oversold territory, suggesting a potential for a near-term price reversal. The stock is trading below its 20-day EMA ($65.47) and 50-day SMA ($63.42), indicating bearish short-term momentum, but remains above its 200-day SMA ($58.49), suggesting a longer-term uptrend is still intact. MACD is slightly positive at 0.26, offering a neutral signal. Key support is identified around the $58.50 level (200-day SMA), while resistance lies at the 50-day SMA of $63.42 and the 20-day EMA of $65.47. Volume has been significantly below average recently, with the latest volume at 321,801 compared to an average of 6.7 million, which suggests a lack of conviction behind current price movements. The chart structure indicates that while oversold conditions may lead to a bounce, sustained upward momentum will require breaking through key moving averages and overcoming insider selling pressure.",
    "Bristol-Myers Squibb Company (BMY) exceeded Q3 2026 EPS estimates by 27.5%, leading to a positive price reaction, indicating potential for improved operational performance.",
    "Insiders have sold $4.6 million worth of BMY stock against $202.2 thousand in purchases, indicating a moderate sell signal and potential lack of management confidence.",
    "Revenue growth is projected to turn negative in 2027 (-3.00%), posing a risk to future earnings and valuation.",
    "The majority of Wall Street analysts maintain a 'Hold' rating, with a median price target of $68.00, suggesting limited near-term upside.",
    "The base case scenario for Bristol-Myers Squibb Company (BMY) suggests a period of consolidation, with potential for a modest recovery towards its median analyst target price of $68.00 over the next 6-12 months, representing a 7.3% upside. The stock's current oversold technical condition could support a short-term bounce, but sustained growth will depend on overcoming slowing revenue projections and competitive pressures. Upside catalysts could include stronger-than-expected pipeline developments or a significant positive earnings surprise that reverses the current insider selling sentiment. Conversely, downside risks include continued revenue contraction, increased competition impacting market share, or adverse clinical trial results. The company's ability to successfully launch new products and manage its patent expirations will be critical for long-term performance."
   ],
   "lists": {
    "ProTips": [
     "Monitor Bristol-Myers Squibb Company's (BMY) pipeline developments closely, as success or failure in clinical trials represents a significant catalyst for future growth.",
     "Given the moderate insider selling, consider waiting for clearer signals of insider confidence or a confirmed technical breakout before initiating or increasing a position.",
     "The company's dividend yield of approximately 3.96% may appeal to income-focused investors, but ensure this is balanced against the company's growth prospects and potential volatility."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Q3 2026 Earnings Beat",
     "text": "Bristol-Myers Squibb Company (BMY) exceeded Q3 2026 EPS estimates by 27.5%, leading to a positive price reaction, indicating potential for improved operational performance.",
     "source": "Earnings Report"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling Signal",
     "text": "Insiders have sold $4.6 million worth of BMY stock against $202.2 thousand in purchases, indicating a moderate sell signal and potential lack of management confidence.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Projected Revenue Decline in 2027",
     "text": "Revenue growth is projected to turn negative in 2027 (-3.00%), posing a risk to future earnings and valuation.",
     "source": "Wall Street Estimates"
    },
    {
     "type": "Neutral",
     "title": "Wall Street Analyst Ratings",
     "text": "The majority of Wall Street analysts maintain a 'Hold' rating, with a median price target of $68.00, suggesting limited near-term upside.",
     "source": "Analyst Consensus"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Bristol-Myers Squibb Company (BMY) trades at a P/E ratio of 14.04, which is below the sector average of 25.5, suggesting a potentially attractive valuation relative to its peers. With an EPS of $4.54, the stock appears reasonably priced based on current earnings. However, projected revenue growth is slowing, with the next year's estimate at -3.00%, which could temper future earnings potential. The company's balance sheet strength and profitability metrics, such as net profit margin and return on equity, would provide further context for this valuation, but are not explicitly detailed. The current valuation, while appearing inexpensive on a P/E basis, must be considered alongside the decelerating revenue growth outlook and the moderate insider selling. Investors should assess whether the current price adequately discounts the future growth challenges. The dividend yield of approximately 3.96% provides a component of return, but the primary driver for stock appreciation will depend on the company's ability to innovate and grow its revenue streams in a competitive pharmaceutical market.",
    "Bristol-Myers Squibb Company recently reported an EPS of $2.04 for the quarter ending July 30, 2026, significantly beating the analyst estimate of $1.60 by 27.5%, leading to a 0.69% price increase. This follows a pattern of mixed earnings performance, with a beat in the prior quarter (Q2 2026) and a substantial EPS beat in Q1 2026, though the Q1 actual EPS of -$0.97 was still a loss compared to an estimated loss of -$3.78. The most recent quarter's strong beat suggests improving operational efficiency or successful product performance, but the overall trend indicates variability in earnings delivery.",
    "A primary risk for Bristol-Myers Squibb Company is the moderate insider selling signal, with $4.6 million in sales versus $202.2 thousand in purchases, indicating a lack of strong conviction from management. Additionally, projected revenue growth is expected to turn negative next year (-3.00%), posing a challenge to future earnings expansion and potentially impacting the stock's valuation. Competition within the pharmaceutical sector remains intense, and any setbacks in the company's drug pipeline could significantly impact its long-term growth prospects."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "130.22B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "14.04"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "4.54"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "3.96%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "68.64"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "42.52"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Neutral RSI Oversold SMA Cross Bullish Price vs SMA Bearish MACD Bullish Golden Cross in effect with the 50-day SMA ($63.42) above the 200-day SMA ($58.49), price is trading below the 50-day SMA, RSI at 28.5 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "28.54"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "0.26"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "63.42"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "58.49"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.15",
    "Correlation with Nasdaq 100 (QQQ)": "+0.02",
    "Correlation with Bitcoin (BTC)": "+0.02",
    "Correlation with Gold (XAU)": "+0.06"
   }
  },
  {
   "id": "trade-plans",
   "title": "BMY Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (28.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$64.62",
    "TARGET 2": "$65.87",
    "TARGET 3": "$67.76",
    "STOP LOSS": "$60.67"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-1.68%",
    "Average Feb return": "+3.30%",
    "Average Mar return": "-1.21%",
    "Average Apr return": "-4.07%",
    "Average May return": "-2.11%",
    "Average Jun return": "+0.56%",
    "Average Jul return": "+1.90%",
    "Average Aug return": "+1.73%",
    "Average Sep return": "-0.76%",
    "Average Oct return": "-1.94%",
    "Average Nov return": "+2.68%",
    "Average Dec return": "+1.93%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.53%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in BMY in September 2016 would be worth about $11,319 today, compared with about $35,030 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BMY today could grow to about $14,660 by 2036 in the base case, with a bull case near $40,655 and a bear case around $5,287. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "BMY Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $73.85 for BMY by 2030 in the base case, from $63.37 today (1.2x over 4 years). The downside path ends near $38.74. These are outcomes of a Monte Carlo simulation run on BMY's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using BMY's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "BMY simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$47.69",
        "$65.84",
        "$90.90"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$43.35",
        "$68.41",
        "$108"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$40.65",
        "$71.08",
        "$124"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$38.74",
        "$73.85",
        "$141"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$37.30",
        "$76.73",
        "$158"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$36.18",
        "$79.72",
        "$176"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$35.28",
        "$82.83",
        "$194"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$34.56",
        "$86.06",
        "$214"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$33.98",
        "$89.42",
        "$235"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$33.50",
        "$92.90",
        "$258"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "TEM Tempus AI Inc NASDAQ $58.74 -4.14%",
     "url": "https://clearank.com/stock/tempus-ai-tem/"
    },
    {
     "text": "GEHC GE HealthCare Technologies Inc. NASDAQ $64.81 -0.5601%",
     "url": "https://clearank.com/stock/ge-healthcare-gehc/"
    },
    {
     "text": "PFE Pfizer Inc. NYSE $27.78 -0.0360%",
     "url": "https://clearank.com/stock/pfizer-pfe/"
    },
    {
     "text": "ISRG Intuitive Surgical Inc. NASDAQ $358.08 +1.37%",
     "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $32.13 -1.74%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    },
    {
     "text": "JNJ Johnson & Johnson NYSE $265.63 -0.2703%",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/"
    },
    {
     "text": "SYK Stryker Corp. NYSE $270.01 -1.95%",
     "url": "https://clearank.com/stock/stryker-syk/"
    },
    {
     "text": "BSX Boston Scientific Corp. NYSE $43.10 -4.14%",
     "url": "https://clearank.com/stock/boston-scientific-bsx/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare BMY",
   "links": [
    {
     "text": "GILD vs BMY Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gild-vs-bmy/"
    },
    {
     "text": "SCHD vs VYM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/schd-vs-vym/"
    },
    {
     "text": "SCHD vs FDVV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/schd-vs-fdvv/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "BMY Insider Trading Analysis",
   "facts": {
    "Bought": "$202.2K",
    "Sold": "$4.6M",
    "Insiders": "15",
    "Avg Transaction": "$792.8K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in BMY",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Feb 6, 2023",
       "cells": [
        "CAFORIO GIOVANNI Chief Executive Officer",
        "Sell",
        "240.0K",
        "$17.9M"
       ]
      },
      {
       "label": "Jul 30, 2021",
       "cells": [
        "VESSEY RUPERT J Officer",
        "Sell",
        "158.4K",
        "$10.8M"
       ]
      },
      {
       "label": "Dec 4, 2017",
       "cells": [
        "LEUNG SANDRA General Counsel",
        "Sell",
        "156.6K",
        "$9.9M"
       ]
      },
      {
       "label": "Sep 13, 2022",
       "cells": [
        "ELKINS DAVID VINCENT Chief Financial Officer",
        "Sell",
        "134.0K",
        "$9.6M"
       ]
      },
      {
       "label": "Aug 13, 2020",
       "cells": [
        "LEUNG SANDRA General Counsel",
        "Sell",
        "141.4K",
        "$8.9M"
       ]
      },
      {
       "label": "Aug 12, 2021",
       "cells": [
        "ELKINS DAVID V Chief Financial Officer",
        "Sell",
        "99.7K",
        "$6.7M"
       ]
      },
      {
       "label": "Mar 16, 2022",
       "cells": [
        "VESSEY RUPERT J Officer",
        "Sell",
        "74.6K",
        "$5.2M"
       ]
      },
      {
       "label": "Mar 2, 2020",
       "cells": [
        "VESSEY RUPERT J Officer",
        "Sell",
        "84.3K",
        "$5.1M"
       ]
      },
      {
       "label": "Jun 6, 2022",
       "cells": [
        "LEUNG SANDRA General Counsel",
        "Sell",
        "65.0K",
        "$4.9M"
       ]
      },
      {
       "label": "Nov 7, 2022",
       "cells": [
        "VESSEY RUPERT J Officer",
        "Sell",
        "45.9K",
        "$3.6M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Bristol-Myers+Squibb+Company&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Bristol-Myers Squibb Company (BMY) stock a buy right now?",
   "answer": "Bristol-Myers Squibb Company (BMY) currently holds a 'Hold' consensus rating from Wall Street analysts, with a median price target of $68.00, suggesting a modest 7.3% upside from its current price of $63.37. While the stock is trading in oversold territory technically, moderate insider selling and slowing revenue growth projections present headwinds."
  },
  {
   "question": "What is Bristol-Myers Squibb Company's (BMY) stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Bristol-Myers Squibb Company's (BMY) stock price is projected to be $73.85 by 2030 under a base case scenario, with a downside projection of $38.74 and an upside projection of $140.77. These are statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "What are the biggest risks facing Bristol-Myers Squibb Company (BMY)?",
   "answer": "The primary risks for Bristol-Myers Squibb Company (BMY) include moderate insider selling, a projected decline in revenue growth next year, and intense competition within the pharmaceutical industry. Pipeline setbacks could also negatively impact future growth."
  },
  {
   "question": "How is Bristol-Myers Squibb Company (BMY) performing in terms of earnings?",
   "answer": "Bristol-Myers Squibb Company (BMY) recently reported a significant EPS beat for the quarter ending July 30, 2026, exceeding estimates by 27.5%. However, earnings performance has been mixed in prior quarters, indicating some variability."
  },
  {
   "question": "What is the dividend yield for Bristol-Myers Squibb Company (BMY)?",
   "answer": "Bristol-Myers Squibb Company (BMY) offers a dividend yield of approximately 3.96%, providing some income return for investors."
  },
  {
   "question": "How does Bristol-Myers Squibb Company (BMY) compare to its sector averages?",
   "answer": "Bristol-Myers Squibb Company (BMY) trades at a P/E ratio of 14.04, which is below the healthcare sector average of 25.5, suggesting a potentially more attractive valuation. However, its projected revenue growth of -3.00% for next year is lower than the sector average of 10.0%."
  },
  {
   "question": "What is the current technical outlook for Bristol-Myers Squibb Company (BMY) stock?",
   "answer": "Bristol-Myers Squibb Company (BMY) is currently in oversold territory with an RSI at 28.5, but it is trading below its short-term moving averages (50-day SMA and 20-day EMA), indicating bearish short-term momentum. The stock remains above its 200-day SMA, suggesting the long-term uptrend is still in place."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "TEM",
    "name": "Tempus AI Inc NASDAQ",
    "price": "$58.74",
    "change": "-4.14%",
    "url": "https://clearank.com/stock/tempus-ai-tem/"
   },
   {
    "ticker": "GEHC",
    "name": "GE HealthCare Technologies Inc. NASDAQ",
    "price": "$64.81",
    "change": "-0.5601%",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "PFE",
    "name": "Pfizer Inc. NYSE",
    "price": "$27.78",
    "change": "-0.0360%",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   },
   {
    "ticker": "ISRG",
    "name": "Intuitive Surgical Inc. NASDAQ",
    "price": "$358.08",
    "change": "+1.37%",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$32.13",
    "change": "-1.74%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   },
   {
    "ticker": "JNJ",
    "name": "Johnson & Johnson NYSE",
    "price": "$265.63",
    "change": "-0.2703%",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$270.01",
    "change": "-1.95%",
    "url": "https://clearank.com/stock/stryker-syk/"
   },
   {
    "ticker": "BSX",
    "name": "Boston Scientific Corp. NYSE",
    "price": "$43.10",
    "change": "-4.14%",
    "url": "https://clearank.com/stock/boston-scientific-bsx/"
   }
  ],
  "comparisons": [
   {
    "ticker": "GILD vs BMY Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gild-vs-bmy/"
   },
   {
    "ticker": "SCHD vs VYM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/schd-vs-vym/"
   },
   {
    "ticker": "SCHD vs FDVV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/schd-vs-fdvv/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   },
   {
    "ticker": "LUGDF",
    "text": "Lundin Gold Inc",
    "url": "https://clearank.com/stock/lugdf-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 9.39%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "EGLD/USD",
    "text": "↓ 9.23%",
    "url": "https://clearank.com/crypto/egld-usd-crypto-analysis/"
   },
   {
    "ticker": "AERO/USD",
    "text": "↑ 8.90%",
    "url": "https://clearank.com/crypto/aero-usd-crypto-analysis/"
   },
   {
    "ticker": "HUT",
    "text": "↑ 8.77%",
    "url": "https://clearank.com/stock/hut-stock-analysis/"
   },
   {
    "ticker": "MRNA",
    "text": "↑ 8.44%",
    "url": "https://clearank.com/stock/moderna-mrna/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABBV",
    "text": "AbbVie",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "AMGN",
    "text": "Amgen",
    "url": "https://clearank.com/stock/amgen-amgn/"
   },
   {
    "ticker": "BIIB",
    "text": "Biogen Inc.",
    "url": "https://clearank.com/stock/biib-stock-analysis/"
   },
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "JNJ",
    "text": "Johnson & Johnson",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "url": "https://clearank.com",
     "sameAs": [
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "email": "info@clearank.com",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise",
     "numberOfEmployees": {
      "@type": "QuantitativeValue",
      "value": "40"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/BMY-bristol-myers-squibb-analysis-2026-06.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/BMY-bristol-myers-squibb-analysis-2026-06.png",
     "width": "1280",
     "height": "720",
     "caption": "Bristol-Myers Squibb (BMY) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/",
        "name": "Bristol-Myers Squibb (BMY) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/#webpage",
     "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/",
     "name": "Bristol-Myers Squibb (BMY) Stock Forecast (2026)",
     "datePublished": "2026-06-17T09:09:29+00:00",
     "dateModified": "2026-09-11T19:02:15+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/BMY-bristol-myers-squibb-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/#breadcrumb"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/writer/clearank/",
     "name": "CleaRank",
     "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.",
     "url": "https://clearank.com/writer/clearank/",
     "image": {
      "@type": "ImageObject",
      "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g",
      "caption": "CleaRank",
      "inLanguage": "en-US"
     },
     "sameAs": [
      "https://clearank.com/",
      "https://twitter.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     },
     "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg"
    },
    {
     "@type": "Article",
     "headline": "Bristol-Myers Squibb (BMY) Stock Forecast (2026)",
     "datePublished": "2026-06-17T09:09:29+00:00",
     "dateModified": "2026-09-11T19:02:15+00:00",
     "author": {
      "@id": "https://clearank.com/writer/clearank/",
      "name": "CleaRank"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "description": "Bristol-Myers Squibb Company (BMY) stock: Healthcare, Drug Manufacturers - General. $130.2B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "name": "Bristol-Myers Squibb (BMY) Stock Forecast (2026)",
     "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/#richSnippet",
     "isPartOf": {
      "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/BMY-bristol-myers-squibb-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/bristol-myers-squibb-bmy/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FinancialProduct",
   "name": "Bristol-Myers Squibb Company (BMY)",
   "tickerSymbol": "BMY",
   "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/",
   "description": "AI-powered financial analysis for Bristol-Myers Squibb Company (BMY) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.",
   "exchange": "NYSE",
   "offers": {
    "@type": "Offer",
    "price": 63.37,
    "priceCurrency": "USD",
    "availability": "https://schema.org/InStock",
    "url": "https://clearank.com/stock/bristol-myers-squibb-bmy/",
    "priceValidUntil": "2026-09-12"
   }
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Bristol-Myers Squibb Company (BMY) stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Bristol-Myers Squibb Company (BMY) currently holds a 'Hold' consensus rating from Wall Street analysts, with a median price target of $68.00, suggesting a modest 7.3% upside from its current price of $63.37. While the stock is trading in oversold territory technically, moderate insider selling and slowing revenue growth projections present headwinds."
     }
    },
    {
     "@type": "Question",
     "name": "What is Bristol-Myers Squibb Company's (BMY) stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Bristol-Myers Squibb Company's (BMY) stock price is projected to be $73.85 by 2030 under a base case scenario, with a downside projection of $38.74 and an upside projection of $140.77. These are statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks facing Bristol-Myers Squibb Company (BMY)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for Bristol-Myers Squibb Company (BMY) include moderate insider selling, a projected decline in revenue growth next year, and intense competition within the pharmaceutical industry. Pipeline setbacks could also negatively impact future growth."
     }
    },
    {
     "@type": "Question",
     "name": "How is Bristol-Myers Squibb Company (BMY) performing in terms of earnings?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Bristol-Myers Squibb Company (BMY) recently reported a significant EPS beat for the quarter ending July 30, 2026, exceeding estimates by 27.5%. However, earnings performance has been mixed in prior quarters, indicating some variability."
     }
    },
    {
     "@type": "Question",
     "name": "What is the dividend yield for Bristol-Myers Squibb Company (BMY)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Bristol-Myers Squibb Company (BMY) offers a dividend yield of approximately 3.96%, providing some income return for investors."
     }
    },
    {
     "@type": "Question",
     "name": "How does Bristol-Myers Squibb Company (BMY) compare to its sector averages?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Bristol-Myers Squibb Company (BMY) trades at a P/E ratio of 14.04, which is below the healthcare sector average of 25.5, suggesting a potentially more attractive valuation. However, its projected revenue growth of -3.00% for next year is lower than the sector average of 10.0%."
     }
    },
    {
     "@type": "Question",
     "name": "What is the current technical outlook for Bristol-Myers Squibb Company (BMY) stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Bristol-Myers Squibb Company (BMY) is currently in oversold territory with an RSI of 28.54, but it is trading below its short-term moving averages (50-day SMA and 20-day EMA), indicating bearish short-term momentum. The stock remains above its 200-day SMA, suggesting the long-term uptrend is still in place."
     }
    }
   ]
  }
 ]
}